홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
VTGN
#4002
Vistagen Therapeutics, Inc. Common Stock
0.607
3
USD
-3.73%
부문:
헬스케어
베이스:
USD
수익 통화:
USD
일일 변동 비율
년간 변동
일일 변동
-3.73%
월간 변동
+17.90%
6달 변화
+17.90%
년간 변동율
+17.90%
이전 종가
0.630
8
Open
0.607
3
Bid
0.607
3
Ask
0.610
3
Low
0.607
3
High
0.607
3
양
6
마켓
주식
헬스케어
VTGN
Open full chart
Financials
Overview
성명
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
6.38 M
6.89 M
7.87 M
27.03 M
29.16 M
—
Valuation ratios
Enterprise value
—
—
—
26.74 M
5.76 M
74.42 M
Price to earnings ratio
—
—
—
-3.55
-1.5
-4.82
Price to sales ratio
—
—
—
98.23
158.83
443.43
Price to cash flow ratio
—
—
—
-4.05
-1.83
-5.63
Price to book ratio
—
—
—
0.91
1.1
1.81
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.17
0.64
2.81
0.24
0.61
0.91
Return on equity %
0.19
0.74
4.9
0.26
0.73
1.12
Return on invested capital %
1 363.97
3 390.02
4 642.81
2 867.66
4 598.63
5 050.58
Gross margin %
100
100
100
100
100
400
Operating margin %
1 646.06
4 308.3
26.11 K
3 103.48
11.52 K
96.99 K
EBITDA margin %
—
—
—
—
—
—
Net margin %
1 646.09
4 306.76
26.1 K
2 759.59
10.58 K
91.71 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
24.85
12.32
3.83
23.55
6.51
22.95
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.02
0.01
0
0.01
0
0.01
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0
—
—
0
—
—
Long term debt to total equity ratio
0
—
—
0
—
—
Per share metrics
Operating cash flow per share
—
-6.86
-7.14
1.33
1.36
1.72
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
10.32
2.39
6.16
2.61
8.21
Net current asset value per share
—
10.76
2.52
6.23
2.66
8.45
Tangible book value per share
—
9.81
1.74
5.9
2.28
7.12
Working capital per share
—
9.88
1.86
5.97
2.25
6.99
Book value per share
—
9.81
1.74
5.9
2.28
7.12
뉴스
비스타젠 테라퓨틱스, 비용 절감 위해 인력 20% 감축
Vistagen Therapeutics reduces workforce by 20 percent to manage costs
비스타젠, TD 코웬 컨퍼런스서 페린 플랫폼 집중 조명
VistaGen at TD Cowen Conference: Pherine Platform in Focus
비스타젠 테라퓨틱스, 이사회 멤버 Paul Edick 사임 발표
Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript
VistaGen 테라퓨틱스, 3분기 AI 활용 분석 발표
Earnings call transcript: VistaGen Therapeutics Q3 2026 highlights AI-driven trial analysis
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates
비스타젠 테라퓨틱스, 파세디에놀 3상 임상시험 목표 미달
Vistagen Therapeutics reports Phase 3 trial for fasedienol did not meet endpoint
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.47%